36 Recruiting Non Small Cell Lung Cancer Phase 2 Clinical Trials
Active phase 2 studies for non small cell lung cancer enrolling across the USA. Verify eligibility and contact site coordinators.
All Non Small Cell Lung Cancer studiesPhase 2 Studies for Non Small Cell Lung Cancer
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
📍 Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
View Study & Checklist ➔Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
📍 Beverly Hills Cancer Center — Beverly Hills, California
View Study & Checklist ➔Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
📍 Research Site — Columbus, Georgia
View Study & Checklist ➔Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
View Study & Checklist ➔Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
📍 Highlands Oncology Group — Springdale, Arkansas
View Study & Checklist ➔Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
📍 UCLA Hematology/Oncology — Santa Monica, California
View Study & Checklist ➔Study of NEO-201 in Solid Tumors Expansion Cohorts
📍 National Cancer Institute — Bethesda, Maryland
View Study & Checklist ➔UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
📍 UC Davis Medical Center — Sacramento, California
View Study & Checklist ➔CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
📍 Mayo Clinic Hospital — Phoenix, Arizona
View Study & Checklist ➔A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
📍 Pacific Cancer Medical Center, Inc — Anaheim, California
View Study & Checklist ➔Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
📍 Rocky Mountain Cancer Center, LLP — Boulder, Colorado
View Study & Checklist ➔Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
📍 Baptist Alliance Miami Cancer Institute — Miami, Florida
View Study & Checklist ➔Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
📍 Georgetown University — Washington D.C., District of Columbia
View Study & Checklist ➔Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
📍 NYU Langone — New York, New York
View Study & Checklist ➔Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
📍 Site 9618 — Tucson, Arizona
View Study & Checklist ➔Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial
📍 St. Joseph's Healthcare Hamilton — Hamilton, Ontario
View Study & Checklist ➔Using ctDNA to Determine Therapies for Lung Cancer
📍 Princess Margaret Cancer Centre — Toronto, Ontario
View Study & Checklist ➔Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
📍 Mayo Clinic Scottsdale — Scottsdale, Arizona
View Study & Checklist ➔Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View Study & Checklist ➔Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)
📍 Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
View Study & Checklist ➔A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
📍 BAPTIST ALLIANCE - MCI (Data Collection Only) — Miami, Florida
View Study & Checklist ➔A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
📍 MD Anderson Cancer Hospital — Houston, Texas
View Study & Checklist ➔A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
📍 FOMAT Oncology — Oxnard, California
View Study & Checklist ➔ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer
📍 University of Miami — Miami, Florida
View Study & Checklist ➔DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
📍 Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
View Study & Checklist ➔BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
📍 Rhode Island Hospital — Providence, Rhode Island
View Study & Checklist ➔Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC
📍 Centre Hospitalier de l'Université de Montréal — Montreal, Quebec
View Study & Checklist ➔Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View Study & Checklist ➔EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
📍 VA Long Beach Healthcare System, Long Beach, CA — Long Beach, California
View Study & Checklist ➔Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
📍 Carolina BioOncology Institute — Huntersville, North Carolina
View Study & Checklist ➔A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
📍 Cancer Treatment Centers of America, Phoenix — Goodyear, Arizona
View Study & Checklist ➔DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer
📍 NYU Langone Health — New York, New York
View Study & Checklist ➔Phase 2 Study of Fingolimod in Lung Cancers
📍 Hollings Cancer Center at Medical University of South Carolina — Charleston, South Carolina
View Study & Checklist ➔IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
📍 St. Anthony's Hospital - BayCare Health System — St. Petersburg, Florida
View Study & Checklist ➔